BeOne Medicines has expanded its partnership with CLL Society, entering into a three-year, $3 million pact to support leukemia and lymphoma patients.
CLL Society is a nonprofit active in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patient education, support and research. BeOne sells the blockbuster BTK inhibitor Brukinsa, which generated $1.4 billion in the third quarter across indications including CLL and SLL. The organizations partnered in 2024 on a push to encourage biomarker testing of newly diagnosed CLL and SLL patients.
The expanded partnership gives CLL Society money to offer education, digital resources and engagement programs. CLL Society is advancing the initiatives to help patients and healthcare providers navigate the treatment landscape.
“Our ambition is to reach every person impacted by CLL/SLL with trusted, physician-curated and up-to-date information about their disease, individual risk factors and treatment options,” Steve Bloom, president and chair of CLL Society, said in a statement.
Some of the money will support the expansion of the biomarker testing education program. CLL Society also plans to add digital resources, including an AI-enabled search tool designed to help patients access “independent, physician-curated resources.” Expert interviews and webinars are other elements of CLL Society’s roadmap.
BeOne’s backing of CLL Society is part of a series of actions supporting leukemia and lymphoma groups. The biotech, then called BeiGene, became the top sponsor of the Leukemia & Lymphoma Society’s Light The Night events in 2024 and committed $5 million to extend its relationship with Blood Cancer United in June.
In May, BeOne began its first major corporate campaign, making former professional soccer goalkeeper Tim Howard the face of its “One Save Changes Everything” project. Another part of BeOne’s marketing triggered an untitled letter from the FDA, which chastised the company in May for using “compelling and attention-grabbing visuals” in a Brukinsa TV ad.